| 词条 | PL-6983 |
| 释义 |
| Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = | image = | width = | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Subcutaneous injection | class = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = 1966957-74-3 | CAS_supplemental = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = | IUPHAR_ligand = | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = | C= | H= | N= | O= | molecular_weight = | SMILES = | StdInChI_Ref = | StdInChI = | StdInChIKey_Ref = | StdInChIKey = }} PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2][3] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.[1][3] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[1][3] The drug has reportedly been in pre-clinical development for all medical indications since 2008. Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[https://web.archive.org/web/20150526024025/http://www.palatin.com/products/6983.asp] The chemical structure of PL-6983 has yet to be made public. See also
References1. ^1 2 {{cite book|author=Natasha Mitchner|title=Hypoactive Sexual Desire Disorder in Women: Implications for Family Practice|year=2009|publisher=Dowden Health Media|url=http://www.oncologypractice.com/fileadmin/jfp_archive/pdf/5807JFP_DIMEsupplv2.pdf}} 2. ^{{cite journal | vauthors = Simon JA | title = Opportunities for intervention in HSDD | journal = J Fam Pract | volume = 58 | issue = 7 Suppl Hypoactive | pages = S26–30 | year = 2009 | pmid = 19825316 | doi = | url = http://www.jfponline.com/fileadmin/jfp_archive/pdf/Supp/SupplJFP0709_HSDD_4.pdf}} 3. ^1 2 {{cite book|author1=Michael L. Krychman|author2=Sandra Finestone|title=100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy|url=https://books.google.com/books?id=poiGbNuPj9sC&pg=PA120|date=25 October 2010|publisher=Jones & Bartlett Publishers|isbn=978-1-4496-1936-7|pages=120–}} External links
5 : Drugs with undisclosed chemical structures|Erectile dysfunction drugs|Female sexual dysfunction drugs|Melanocortin receptor agonists|Peptides |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。